Caplin Point Laboratories growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+12.9%+14.4%+15.5%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+17.6%+17.3%+25.0%
+18.4%+16.7%+25.7%
+20.1%+17.3%+22.4%
+19.5%+17.2%+21.3%
+26.1%+19.0%+23.1%
+25.8%+23.0%+23.0%
+21.0%+39.0%+14.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CAPLIPOINT₹2,376.10

Caplin Point Laboratories Ltd.

· Pharma & Health
₹ CrorePeersAJANTPHARMERISGLANDBLUEJETCONCORDBIOACUTAASEMCUREGRANULESMcap ₹18,058 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+15.5+14.4+12.9—
EBITDA Growth—+25.0+17.3+17.6—
EBIT Growth—+25.7+16.7+18.4—
Net Income Growth—+22.4+17.3+20.1—
EPS Growth—+21.3+17.2+19.5—
Total Assets Growth—+23.1+19.0+26.1—
Total Equity Growth—+23.0+23.0+25.8—
Cash from Operations Growth—+14.5+39.0+21.0—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.